MENU
ANIP
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

ANIP stock forecast, quote, news & analysis

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
ANIP
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for ANIP with price predictions
Oct 21, 2026

ANIP's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ANIP turned positive on October 19, 2026. Looking at past instances where ANIP's MACD turned positive, the stock continued to rise in 47 of 58 cases over the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 35 of 48 cases where ANIP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ANIP as a result. In 71 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

Following a +0.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANIP advanced for three days, in 213 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

Bearish Trend Analysis

The 10-day RSI Indicator for ANIP moved out of overbought territory on September 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 16 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.

ANIP moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANIP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.

ANIP broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ANIP entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 40 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.779) is normal, around the industry mean (11.138). P/E Ratio (14.957) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (1.856) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (1.657) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. ANIP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.33B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -3%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was 10%. RGC experienced the highest price growth at 33%, while GLAS experienced the biggest fall at -37%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 16%. For the same stocks of the Industry, the average monthly volume growth was 25% and the average quarterly volume growth was -0%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 44
P/E Growth Rating: 59
Price Growth Rating: 57
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
ANIP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of branded and generic prescription pharmaceuticals

Industry PharmaceuticalsGeneric

Industry
Pharmaceuticals Other
Address
210 Main Street West
Phone
+1 218 634-3500
Employees
970
Web
https://www.anipharmaceuticals.com